A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03163810|
Recruitment Status : Withdrawn (Difficulty with recruitment)
First Posted : May 23, 2017
Last Update Posted : January 28, 2020
|Condition or disease||Intervention/treatment||Phase|
|Nonalcoholic Steatohepatitis||Device: Erchonia Verju Laser Device: Erchonia EVRL Laser||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Evaluation of the Effect of the Erchonia Verjú™ and EVRL Lasers on Reducing Aminoalanine Transaminase (ALT) in Individuals With Nonalcoholic Steatohepatitis (NASH)|
|Actual Study Start Date :||February 6, 2017|
|Actual Primary Completion Date :||December 13, 2017|
|Actual Study Completion Date :||December 13, 2017|
Experimental: Erchonia Verju and EVRL Laser
The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.
The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously
Device: Erchonia Verju Laser
The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
Device: Erchonia EVRL Laser
The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
- Percent (%) change from Baseline to Subject Study Endpoint evaluation in aminoalanine transaminase (ALT) level. [ Time Frame: 2 or 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03163810
|United States, Arizona|
|Meridian Integrative Medicine|
|Scottsdale, Arizona, United States, 85250|
|Principal Investigator:||Charles M Schron, MD|